Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZDL | ISIN: US68218J1034 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:53
1,505 US-Dollar
+9,06 % +0,125
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
OMNIAB INC Chart 1 Jahr
5-Tage-Chart
OMNIAB INC 5-Tage-Chart

Aktuelle News zur OMNIAB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls2
OMNIAB Aktie jetzt für 0€ handeln
08.05.OmniAb, Inc. - 10-Q, Quarterly Report-
08.05.OmniAb GAAP EPS of -$0.17 in-line, revenue of $4.2M misses by $0.29M1
08.05.OmniAb, Inc. - 8-K, Current Report1
06.05.Veraxa and OmniAb to develop bispecific ADC tumour programme2
05.05.Voyager Acquisition Corp.: VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program118ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition...
► Artikel lesen
05.05.VERAXA Biotech Enters Co-Discovery Alliance with OmniAb1
05.05.VERAXA Biotech GmbH: VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program409Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech...
► Artikel lesen
21.04.OmniAb expands board with two new directors2
21.04.OmniAb, Inc. - 8-K, Current Report1
18.03.OmniAb, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
18.03.OmniAb, Inc. - 10-K, Annual Report1
18.03.OmniAb, Inc. - 8-K, Current Report2
12.11.24OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights274EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program...
► Artikel lesen
08.08.24OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights294EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. "Second...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1